General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0ROKMU
ADC Name
SG11202408662TA ADC-C1
Synonyms
ADC-C1
   Click to Show/Hide
Organization
BEIGENE, LTD.
Drug Status
Investigative
Drug-to-Antibody Ratio
8.12
Structure
Antibody Name
Ifinatamab
 Antibody Info 
Antigen Name
CD276 antigen (CD276)
 Antigen Info 
Payload Name
DX-8951 derivative (DXd)
 Payload Info 
Therapeutic Target
DNA topoisomerase 1 (TOP1)
 Target Info 
Linker Name
Mc-Gly-Gly-Phe-Gly
 Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Effective Concentration (EC50) 
0.022
nM
CVCL_1559
Minimally invasive lung adenocarcinoma
Half Maximal Effective Concentration (EC50) 
0.034
nM
CVCL_1453
Lung small cell carcinoma, Small cell lung cancer
Half Maximal Effective Concentration (EC50) 
2.201
nM
CVCL_1561
Lung papillary adenocarcinoma
Half Maximal Effective Concentration (EC50) 
> 100
nM
CVCL_0418
Breast adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 0.022 nM High B7H3 expression (B7H3 +++)
Method Description
Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model Minimally invasive lung adenocarcinoma H358 cells CVCL_1559
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 0.034 nM Positive B7H3 expression (B7H3+++/++)
Method Description
Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model Lung small cell carcinoma, Small cell lung cancer H1048 cells CVCL_1453
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 2.201 nM Positive B7H3 expression (B7H3+++/++)
Method Description
Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model Lung papillary adenocarcinoma H441 cells CVCL_1561
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) > 100 nM Negative B7H3 expression (B7H3-)
Method Description
Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model Breast adenocarcinoma MDA-MB-453 cells CVCL_0418
References
Ref 1 Antibody drug conjugates